劲方医药 Mediaroom - PR Newswire APAC

GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation

SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology compa...

2024-08-23 19:30 3883

GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation

SHANGHAI, June 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology compa...

2024-06-19 19:00 1902

GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechn...

2024-06-02 07:13 2918

GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer

SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology comp...

2024-04-19 19:00 2183

GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biote...

2024-04-09 19:00 1670

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biote...

2024-04-09 19:00 1374

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

SHANGHAI, March 28, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology comp...

2024-03-28 19:00 2242

GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia

SHANGHAI, Jan. 11, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology compa...

2024-01-11 19:00 1847

China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation

SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology compa...

2023-11-24 19:00 2236

GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

SHANGHAI, Oct. 10, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology compa...

2023-10-10 19:00 1484

2023 ASCO | Multi-center Data for Combination Study of GenFleet's GFH018 (TGF-β R1 inhibitor) with Anti-PD-1 Antibody Demonstrates Significant Potential to Enhance Efficacy of Immune Checkpoint Inhibitors among ICI-naïve Patients

SHANGHAI and CHICAGO, June 6, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechn...

2023-06-06 19:00 2009

GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting

SHANGHAI, March 9, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology compa...

2023-03-09 19:00 1605

GenFleet receives EMA approval for phase Ib/II study of GFH925 (KRAS G12C inhibitor) in combination with ERBITUX® (cetuximab) treating patients with advanced NSCLC in first-line setting

SHANGHAI, March 1, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology compa...

2023-03-01 19:00 1940

GenFleet Therapeutics and Merck Enter into Trial Collaboration to Initiate Study Investigating Combination Therapy of GFH925 (KRAS G12C inhibitor) and ERBITUX® (cetuximab)

SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology compa...

2022-12-19 19:00 1498

GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)

SHANGHAI and NEW ORLEANS, Nov. 28, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage bio...

2022-11-28 19:00 2738

GenFleet Therapeutics to Present Data from Phase I Trial of GFH018 Monotherapy at the 2022 European Society for Medical Oncology Annual Meeting

SHANGHAI and PARIS, Sept. 7, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechno...

2022-09-07 19:00 2696

GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology compa...

2022-08-18 19:00 1733

GenFleet Therapeutics Raises $75 Million in Series C Financing Led by Huagai Capital, to Advance Innovative Pipeline Highlighting Cutting-edge Therapies

SHANGHAI, Dec. 31, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology comp...

2021-12-31 19:00 2050

GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research

PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a cl...

2021-10-21 08:05 1793

GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor

GUANGZHOU, China, Sept. 29, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnol...

2021-09-30 08:05 1858

Latest News